Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy


Author index

Page Path
HOME > Browse Articles > Author index
Jae Pil Han 2 Articles
The Early Onset of Disease May Be a Risk Factor for Decreased Bone Mineral Density in Patients with Inflammatory Bowel Disease
Hwa Jong Kim, Su Jin Hong, Young Woo Jeon, Jae Pil Han, Seung Hyo Han, Jee Heon Kang, Jae Woong Tae, Hee Sook Lim, Hee Kyung Kim, Bong Min Ko, Moon Sung Lee
Clin Endosc 2013;46(1):71-76.   Published online January 31, 2013
AbstractAbstract PDFPubReaderePub

The pathogenesis of bone loss in patients with inflammatory bowel disease (IBD) is complex, multifactorial, and only partly understood. We aimed to examine the extent and risk factors of bone mass reduction and to analyze the impact of early onset of a disease before attaining peak bone mass in IBD patients.


We compared the risk factors for osteoporosis and BMD at the lumbar spine and the hip bone in IBD patients.


A total of 44 patients with IBD were enrolled. Twenty-one and 23 patients were diagnosed as IBD before and after the age of 30 and designated as group A and group B, respectively. Group A had significant bone mass reduction at the lumbar spine than group B (BMD, 1.01±0.10 vs. 1.14±0.17, p<0.01; T-score, -1.22±0.84 vs. -0.08±1.39, p<0.01; Z-score, -1.11±0.81 vs. -0.03±1.32, p<0.01, respectively). Multivariate analysis showed that patients diagnosed as IBD before the age of 30 had possible risk factor of bone mass reduction (hazard ratio, 3.96; p=0.06).


Bone mass reduction was more severe in patients who were diagnosed with IBD before the age of 30 than in those diagnosed after the age of 30.


Citations to this article as recorded by  
  • Small and Large Intestine (II): Inflammatory Bowel Disease, Short Bowel Syndrome, and Malignant Tumors of the Digestive Tract
    Yolanda Ber, Santiago García-Lopez, Carla J. Gargallo-Puyuelo, Fernando Gomollón
    Nutrients.2021; 13(7): 2325.     CrossRef
  • Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan
    Ichiro Takeuchi, Yoichiro Kaburaki, Katsuhiro Arai, Hirotaka Shimizu, Yuri Hirano, Satoru Nagata, Toshiaki Shimizu
    Journal of Gastroenterology and Hepatology.2020; 35(4): 593.     CrossRef
  • Advances in nutritional therapy in inflammatory bowel diseases: Review
    Andrzej Wędrychowicz
    World Journal of Gastroenterology.2016; 22(3): 1045.     CrossRef
  • Nutritional aspect of pediatric inflammatory bowel disease: its clinical importance
    Seung Kim, Hong Koh
    Korean Journal of Pediatrics.2015; 58(10): 363.     CrossRef
  • Biomarkers of Cartilage and Surrounding Joint Tissue
    Anne S Siebuhr, Yi He, Natasja S Gudmann, Aurelie Gram, Cecilie F Kjelgaard-Petersen, Per Qvist, Morten A Karsdal, Anne C Bay-Jensen
    Biomarkers in Medicine.2014; 8(5): 713.     CrossRef
  • Crohn's disease and growth deficiency in children and adolescents
    Marco Gasparetto
    World Journal of Gastroenterology.2014; 20(37): 13219.     CrossRef
  • Can Early Onset of Disease Be One of the Risk Factors for Low Bone Mineral Density in Patients with Inflammatory Bowel Disease?
    Kwang An Kwon, Yang Suh Ku
    Clinical Endoscopy.2013; 46(1): 5.     CrossRef
  • 6,172 View
  • 53 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
A Hypereosinophilic Syndrome Presenting as Eosinophilic Colitis
Young Woo Jeon, Su Jin Hong, Hwa Jong Kim, Jae Pil Han, Hee Kyung Kim, Bong Min Ko, Sung Kyu Park, Moon Sung Lee
Clin Endosc 2012;45(4):444-447.   Published online November 30, 2012
AbstractAbstract PDFPubReaderePub

Hypereosinophilic syndrome (HES) has three defining features: marked hypereosinophilia for at least 6 months, no confirmed etiology for the eosinophilia, and eosinophilia-related symptoms or organ dysfunction. However, a shorter period of hypereosinophilia with symptoms requiring eosinophil-lowering therapy is also acceptable. We report a case of HES presenting as eosinophilic colitis. Although hypereosinophilia was present for 3 months, this patient needed to be treated with eosionphil-lowering therapy for severe hematochezia. After systemic corticosteroid therapy, symptoms caused by organ involvement were dramatically improved.


Citations to this article as recorded by  
  • Hyper-eosinophilic syndrome: An uncommon cause of chronic abdominal pain in an elderly male
    Dibya L Praharaj, Bipadabhanjan Mallick, Preetam Nath, Sarat C Panigrahi, Anil C Anand, Rajkumar Sharma
    Tropical Doctor.2021; 51(4): 640.     CrossRef
  • Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease
    Gregory M. Constantine, JeanAnne Ware, Thomas Brown, Lauren Thumm, Natasha Kamal, Sheila Kumar, David Kleiner, Irina Maric, Amy D. Klion
    The Journal of Allergy and Clinical Immunology: In Practice.2020; 8(6): 2089.     CrossRef
  • Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review
    Vivian C. Nanagas, Anna Kovalszki
    Clinical Reviews in Allergy & Immunology.2019; 57(2): 194.     CrossRef
  • Hypereosinophilic Syndrome Presenting as Intussusception in Adults
    Nuri Chon, WooJung Kim, Sang Young Park, Kwang Hyun Kim
    Korean Journal of Medicine.2014; 87(5): 585.     CrossRef
  • Syndrome hyperéosinophilique de type myéloprolifératif révélé par une ascite : à propos d’un cas
    M. Boudabbous, H. Mnif, H. Bellaj, K. Yaïch, L. Chtourou, L. Mnif, A. Amouri, N. Tahri
    Journal Africain d'Hépato-Gastroentérologie.2014; 8(2): 89.     CrossRef
  • Recurrent cutaneous necrotizing eosinophilic vasculitis: a case report and review of the literature
    Wenfei Li, Wang Cao, Haiyan Song, Yanxia Ciu, Xianmei Lu, Furen Zhang
    Diagnostic Pathology.2013;[Epub]     CrossRef
  • 7,737 View
  • 47 Download
  • 6 Crossref
Close layer

Clin Endosc : Clinical Endoscopy Twitter Facebook
Close layer